TVTX: Filspari 2Q26 Sales in Focus After FSGS Approval; New Filspari IgAN Patent Pushes Exclusivity to 2037 and Increases Our PT to $65 (from $56); Reiterate Buy, Best Idea

Research evidence excerpt

TVTX: Filspari 2Q26 Sales in Focus After FSGS Approval; New Filspari IgAN Patent Pushes Exclusivity to 2037 and Increases Our PT to $65 (from $56); Reiterate Buy, Best Idea

oral or written market commentary or trading strategies to Guggenheim Securities' clients and our employees

trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim and certain of our affiliates conduct

an investment management business, trade for their own accounts, and may make investment decisions that are inconsistent with the recommendations

or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as

principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a

principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim research

and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account

the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation

in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of

investments referred to in this research and the income from them will fluctuate.